Integrating machine learning models trained on WHO GLASS antimicrobial resistance surveillance data with agent-based prescribing policy simulators will improve forecast accuracy of regional AMR emergence compared to either approach alone.

MedicineApr 6, 2026Evaluation Score: 73%

Adversarial Debate Score

57% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

ChatGPT: The hypothesis is clearly falsifiable and logically plausible, but only one relevant paper (abx_amr_simulator) directly supports the integration of simulation and machine learning in AMR; the others are focused on quantum algorithms and unrelated domains, offering little direct evidence or counte...

Mistral: The hypothesis is falsifiable and aligns with the cited abx_amr_simulator paper, but the other papers are irrelevant, and counterarguments (e.g., data quality, model bias) weaken its robustness.

Claude: The hypothesis is falsifiable in principle and partially grounded in one relevant paper (abx_amr_simulator), which provides an agent-based simulation environment for AMR prescribing dynamics; however, the remaining papers are almost entirely about quantum computing and molecular simulation, offer...

Supporting Research Papers

MQTE: A Measurement-Based Quantum Algorithm for Robust Energy Spectrum Estimation in the NISQ Era
Extracting energy spectra from quantum Hamiltonians is a fundamental task for quantum simulation, yet remains challenging on noisy intermediate-scale quantum (NISQ) devices. We propose Measured Quantu...
abx_amr_simulator: A simulation environment for antibiotic prescribing policy optimization under antimicrobial resistance
Antimicrobial resistance (AMR) poses a global health threat, reducing the effectiveness of antibiotics and complicating clinical decision-making. To address this challenge, we introduce abx_amr_simula...
Local strategies are pretty good at computing Boolean properties of quantum sequences
Quantum memory is a scarce and costly resource, yet little is known about which learning tasks remain feasible under severe memory constraints. We study the problem of computing global properties of q...
Machine Learning for analysis of Multiple Sclerosis cross-tissue bulk and single-cell transcriptomics data
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system whose molecular mechanisms remain incompletely understood. In this study, we developed an end-to-end machine learn...
Universal Persistent Brownian Motions in Confluent Tissues
Biological tissues are active materials whose non-equilibrium dynamics emerge from distinct cellular force-generating mechanisms. Using a two-dimensional active foam model, we compare the effects of t...

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

A hybrid forecasting system — consisting of (a) a machine learning model trained on WHO GLASS antimicrobial resistance surveillance time series (country/pathogen/antibiotic-level resistance proportions, 2016–present) and (b) an agent-based model (ABM) simulating antibiotic prescribing behavior, pathogen transmission, and resistance selection pressure at regional/facility scale — when combined via ensemble or ML-informed-ABM-parameterization architecture, will produce a 12-month-ahead forecast of regional resistance-proportion emergence (e.g., % of E. coli isolates resistant to third-generation cephalosporins in a given WHO region) with lower mean absolute error (MAE) and better calibration (CRPS) than either (i) the ML model alone or (ii) the ABM alone, evaluated on held-out country-years not used in training/calibration.

Disproof criteria:

Hybrid model MAE is statistically indistinguishable from (within 1 SE of) the better of the two standalone models across ≥3 independent pathogen-antibiotic-region test sets (paired bootstrap, α=0.05).
Hybrid model shows worse calibration (CRPS) than the ML-only baseline, indicating the ABM component adds noise rather than signal.
Improvement is present only in-sample/backtest but vanishes in true prospective forecasting (next 12 months of newly released GLASS data), indicating overfitting to historical policy-resistance coupling.
No statistically significant improvement after correcting for multiple comparisons across the ≥10 pathogen-antibiotic combinations tested.

Spine & Adversarial Read

highGLASS data has known, substantial reporting-quality heterogeneity across countries (differing lab standards, sampling bias, inconsistent isolate counts) — any forecast 'improvement' may reflect data-quality artifacts rather than genuine methodological superiority of the hybrid architecture.
Protocol restricts to WHO tier 1–2 reporting-quality countries with ≥6 years consistent data, but this EVP does not yet include a formal data-quality-adjusted sensitivity analysis (e.g., re-running with a data-quality covariate or restricting to ECDC EARS-Net as a higher-quality validation set). This gap should be closed before claiming generalizability beyond the initial 15-country sample.
highWhy an agent-based model specifically, rather than a simpler mechanistic compartmental (SIR-type) model or a pure Bayesian hierarchical time-series model with policy covariates? The choice of ABM as the mechanistic component is not justified against these cheaper, more tractable alternatives.
Not resolved in current design — the EVP asserts ABM value (simulating counterfactual policy shifts, agent heterogeneity) but does not include a required ablation comparing ABM against a simpler compartmental+covariate baseline. This is a methodology-justification gap: Step 9's sensitivity analysis should be extended to include this comparison as a mandatory pre-registered arm, not optional follow-up.
mediumA 12-month forecast horizon with only 4 rolling-origin folds per pathogen-antibiotic pair (n=4 effective test points per pair) gives very low statistical power to detect the claimed 15% MAE improvement robustly; results could be dominated by 1-2 anomalous years (e.g., COVID-19 disruption to prescribing patterns in 2020-2021).
Partially addressed via multiple-comparison correction across pairs, but the small number of independent forecast origins remains a genuine statistical power limitation. Recommend explicitly excluding or separately stratifying COVID-era origins (2020-2021) as a robustness check, and treating any single-pair, single-origin 'success' as insufficient for the stated success criteria (which correctly require ≥2 of 3 pairs — this partially mitigates but does not eliminate the concern).

Experimental Protocol

Minimum viable test (MVT): Select 3 pathogen-antibiotic pairs with strongest GLASS data density (e.g., E. coli/3GC-resistance, K. pneumoniae/carbapenem-resistance, S. aureus/methicillin-resistance) across 15 countries with ≥6 years GLASS reporting. Train (1) gradient-boosted/LSTM ML baseline on GLASS time series + covariates (consumption, GDP, healthcare access), (2) calibrated ABM (prescribing agents, transmission compartments, resistance selection), (3) hybrid — ML forecasts feed ABM behavioral parameters, ABM outputs feed back as ML features (stacked ensemble). Backtest on rolling-origin splits (train ≤ year t, forecast t+1), repeated for 4 origins per pair. Primary comparison: MAE and CRPS across held-out years, paired significance test.

Required datasets:

WHO GLASS AMR surveillance data (public, country/pathogen/antibiotic resistance proportions, 2016–2024)
WHO GLASS antimicrobial consumption module (AMC) — national antibiotic use volumes by class
WHO AWaRe classification database (stewardship categorization)
National/regional prescribing policy timelines (stewardship program launch dates — manually curated from WHO/CDC/ECDC reports)
Population and healthcare access covariates (World Bank, UN data) for ABM calibration
Optional secondary validation: ECDC EARS-Net (Europe-specific higher granularity) for cross-database replication
Compute environment: Python (scikit-learn/XGBoost/PyTorch for ML; Mesa or custom Julia ABM framework for agent simulation)

Success:

Hybrid MAE reduced by ≥15% relative to best standalone model, significant at p<0.05 after multiple-comparison correction, in ≥2 of 3 pathogen-antibiotic pairs.
CRPS improvement ≥10% (better probabilistic calibration) for hybrid vs. both baselines.
Prospective (true out-of-sample, not backtest) forecast on next GLASS data release confirms ≥1 of the 3 pairs retains ≥10% MAE improvement.
Sensitivity analysis shows hybrid gain is robust (not an artifact of ABM overfitting) across ±20% parameter perturbation.

Failure:

Hybrid shows <5% MAE improvement or improvement not significant after correction in any of 3 tested pairs.
Prospective validation shows hybrid gain disappears (backtest-only artifact).
ABM calibration fails to converge (ABC acceptance rate <1%) indicating the simulator cannot be meaningfully fit to GLASS data, undermining feasibility of the entire hybrid architecture.
Data sparsity forces exclusion of >50% of intended country-year observations, invalidating statistical power calculations.

180

GPU hours

150d

Time to result

$35,000

Min cost

$210,000

Full cost

ROI Projection

Implementation Sketch

# Phase 1: Data pipeline
glass_data = load_and_harmonize(GLASS_resistance, GLASS_consumption, AWaRe, covariates)
splits = rolling_origin_split(glass_data, origins=[2020,2021,2022,2023], horizon=12)

# Phase 2: ML baseline
for pair in pathogen_antibiotic_pairs:
    ml_model = XGBoostRegressor(lag_features, consumption_features, covariates)
    ml_model.fit(train_split)
    ml_forecast = ml_model.predict(test_split)

# Phase 3: ABM
class PrescribingAgent(Agent):
    def choose_antibiotic(self, stewardship_policy, local_resistance_rate): ...
class TransmissionModel(Model):
    def step(self):
        apply_selection_pressure()
        update_resistance_proportions()

abm = calibrate_ABC(TransmissionModel, target=historical_resistance_trajectory,
                     tolerance=0.05, n_particles=5000)
abm_forecast_ensemble = abm.run_forward(steps=12, n_sims=1000)

# Phase 4: Hybrid stacking
hybrid_features = concat(ml_forecast, abm_forecast_ensemble.mean(), abm_forecast_ensemble.var())
stacker = RidgeRegressor()
stacker.fit(hybrid_features_train, actual_resistance_train)
hybrid_forecast = stacker.predict(hybrid_features_test)

# Phase 5: Evaluation
for model in [ml_model, abm, hybrid]:
    compute_MAE(model, test_split)
    compute_CRPS(model, test_split)
paired_bootstrap_test(hybrid_forecast, ml_forecast, abm_forecast, n=10000)

Abort checkpoints:

Day 20: If ABC calibration of ABM fails to converge (acceptance rate <1% after 50,000 simulations) on ≥2 of 3 pathogen-antibiotic pairs, abort ABM branch and re-scope to ML-only sensitivity study.
Day 60: If backtest MAE improvement of hybrid over best baseline is <5% on the first completed pair, halt further pair expansion pending root-cause diagnosis (ablation study on ABM contribution).
Day 100: If prospective blind-forecast validation (against newly released GLASS data) shows no replication of backtest gains, abort claim of prospective utility and report as backtest-only finding.

NAMED_EXPERTS: []

CLOSEST_EXISTING_WORK: []

NOVELTY_NARROWING_REQUIRED: false

SPINE_STATEMENT: This hypothesis tests whether combining an ML model trained on WHO GLASS surveillance data with an agent-based prescribing-policy simulator produces more accurate 12-month regional AMR emergence forecasts than either method used alone.

Source

AegisMind Research

Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started